OREANDA-NEWS. LifeWatch AG (SIX Swiss Exchange: LIFE), a market leader in the development and sale of digital health solutions primarily for remote cardiac monitoring and sleep apnea diagnostics, realized a turnover of USD 98.47 million for the business year 2014, 8.1% more than in the previous year (2013: USD 91.06 million). In particular, the second half year saw a significant reduction in costs, which offsets the operative losses from the first half year. The EBIT for the second semester amounted to USD 4.43 million following the negative result in the first six months of USD 4.13 million. In total the EBIT for the business year 2014 amounted to USD 0.30 million (2013: -2.089 million). The positive business development in the second half of the year resulted in an EBITDA of USD 7.47 million for this period which more than offset the negative first half year numbers. The net loss of USD 2.73 million (2013: net profit USD 2.92 million) resulted primarily from a tax charge of USD 2.54 million, in comparison to a tax credit of over USD 5 million which was recorded in the previous year.

 About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE) in Switzerland, is a leading provider of digital health systems and wireless telemetry monitoring services. The LifeWatch services deliver important information to doctors for appropriate treatment of their patients and better treatment results.  LifeWatch has operative subsidiaries in the USA, Switzerland, Macedonia and Israel and is the parent concern for LifeWatch Services, Inc. and LifeWatch Technologies, Ltd.  LifeWatch Services, Inc. is a leading US provider of cardiac monitoring services as well as sleep analysis for the diagnosis of obstructive sleep apnoea syndromes (OSAS).  LifeWatch Technologies, Ltd. in Israel is a leading developer and producer of digital health products.